Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Anne Moscona · WASHINGTON UNIVERSITY · 2024 · $44,108,652 — SUMMARY. The Vaccines and Therapeutic Antibodies to Respirovirus, Rubulavirus, Peribunyavirus and Phenuivirus (R2P2) ReVAMPP Center will utilize both well-defined and novel approaches to develop prototype vaccines and human monoclonal antibody (mAb)-based treatments for rapid response to viruses fro…
Michael Anthony Moody · DUKE UNIVERSITY · 2024 · $2,387,026 — Project Abstract - A Global Syphilis Vaccine Targeting Outer Membrane Proteins of Treponema pallidum The scientific premise of this CRC proposal rests upon our three decades of work defining the molecular architecture of the outer membrane (OM) of Treponema pallidum subsp. pallidum (TPA), coupled wi…
Jeremy Phillip Kamil · LOUISIANA STATE UNIV HSC SHREVEPORT · 2024 · $142,711 — This project focuses on the role of glycobiology in human cytomegalovirus (HCMV) immune evasion strategies. Our long-term goal is to understand how the virus exploits host protein glycosylation pathways to shield its virions and decorate the surfaces of infected cells with oligosaccharide patterns t…
Roger Sciammas · UNIVERSITY OF CALIFORNIA-IRVINE · 2024 · $86,698 — Project summary: The vast majority of mammalian genes produce alternatively processed mRNAs through alternative splicing and alternative polyadenylation (APA). Different mRNA isoforms produced from the same gene can encode distinct proteins and/or they may be differentially regulated. Recent studies…
Richard Thomas Wyatt · SCRIPPS RESEARCH INSTITUTE, THE · 2024 · $976,445 — PROJECT SUMMARY A broadly effective HIV vaccine remains a high priority to reduce the spread of this highly pathogenic virus in the human population. Neutralizing antibodies, broadly cross-neutralizing are highly likely needed to be generated from evolving vaccine candidate immunogens, either protei…
John Ramunas · REJUVENATION TECHNOLOGIES, INC. · 2024 · $520,303 — Abstract Rejuvenation Technologies Inc. (RTI) seeks to improve the tools required for clinical translation of intravenously- infused RNA lipid nanoparticle (LNP) therapeutics. While there is abundant work on RNA LNP vaccines, the requirements for intravenously-infused LNPs are significantly more dem…
Olivia Swanson · SCRIPPS RESEARCH INSTITUTE, THE · 2024 · $35,974 — Project Summary/Abstract. A small fraction of individuals infected with HIV-1 generate antibodies that can potently neutralize diverse circulating strains of HIV-1. Such broadly neutralizing antibodies (bnAbs) have provided sterilizing immunity in passive immunization studies in animal models. There…
Troy Michael Bankhead · WASHINGTON STATE UNIVERSITY · 2024 · $382,500 — Summary The ability of Borrelia burgdorferi to cause Lyme disease is highly dependent on its capacity to establish a successful infection upon entering the mammalian host. Moreover, survival of the pathogen in nature is completely dependent on its enzootic life cycle involving both a tick and reser…
ELLIS L REINHERZ · DANA-FARBER CANCER INST · 2024 · $640,540 — ABSTRACT Programming the immune system to detect neoantigens and destroy tumors is critical for effective immunotherapy. Until now, bioinformatic prediction of neoepitopes on tumors from Next Generation Sequencing (NGS) information has been used alone or in conjunction with immunological assays to i…
ERIC T. KOOL · STANFORD UNIVERSITY · 2024 · $623,371 — Work in the last decade from many labs has underlined the critical importance of RNA-mediated cellular pathways, and clear connections of specific RNAs to human health. RNAs are increasingly viewed both as appealing therapeutic targets, and as therapeutic agents themselves. We hypothesize that obtai…
Genoveffa Franchini · DIVISION OF BASIC SCIENCES - NCI · 2024 · $2,580,801 — Development of a vaccine for HIV is necessary as 38 million people are now infected worldwide, including 1.1 million in the US. The annual estimated HIV incidence is 1.5 million global infections per year, with 38,000 in the US. Moreover, adolescent girls and women are heavily impacted by the virus …
Lbachir BenMohamed · UNIVERSITY OF CALIFORNIA-IRVINE · 2024 · $409,999 — SUMMARY/ABSTRACT Herpes simplex type virus-1 (HSV-1) infects over 3.72 billion people worldwide, including 200 million individuals in the United States. Following primary infection of the cornea, HSV-1 establishes latency in sensory neurons of the trigeminal ganglia (TG). Reactivation of HSV-1 from …
Pranav Danthi · TRUSTEES OF INDIANA UNIVERSITY · 2024 · $379,747 — Mammalian orthoreovirus (MRV) genomic RNA is detected by host cells to induce an innate immune response. Detection of MRV RNA also contributes to the induction of cell death. Because viral genomic RNA remains contained within particles throughout infection, how the RNA becomes exposed and accumulate…
Robert L. Ferris · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2024 · $250,000 — Optimization of a modified immunotherapeutic LANA antigen for use in treating persons with HIV/AIDS and refractory KSHV-related cancers (Immuno/Microenvironment). ABSTRACT This PA-20-272 administrative supplement to the UPMC Hillman Cancer Center Support Grant (P30CA047904) is directly responsive to…
David Anthony Hendrix · OREGON STATE UNIVERSITY · 2024 · $304,159 — PROJECT SUMMARY: There is a need for integrative data analyses that anchor transcriptomic research in contexts predictive of human health, as illustrated by growing awareness of disease-associated synonymous transcript variants and RNA biotechnologies such as mRNA vaccines. To help uncover sequence …
Siyuan Ding · WASHINGTON UNIVERSITY · 2024 · $393,750 — Project Summary Rotaviruses (RVs) are a medically important human pathogen and the predominant cause of severe gastroenteritis, vomiting, and diarrhea in infants and young children worldwide. RVs are also a great model to interrogate the antiviral responses at the host mucosal surfaces. Our overall…
Richard Thomas Wyatt · SCRIPPS RESEARCH INSTITUTE, THE · 2024 · $3,442,683 — Neutralizing antibodies are likely to be required for an effective HIV-1 vaccine. However, few candidate vaccines efficiently elicit broadly neutralizing antibodies (bNAbs) following vaccination. Recently, the VRC working group has elicited fusion peptide-directed bNAbs in guinea pigs and non-human …
Zhi Q. Yao · JAMES H QUILLEN VA MEDICAL CENTER · 2024 — SUMMARY The overall goal of this proposal is to elucidate the mechanisms by which chronic HIV infection promotes telomere attrition and T cell aging, leading to hepatitis B virus (HBV) vaccine hypo-responsiveness. To this end, we will use a model that emulates HBV vaccine response in the setting of …
Sean PJ Whelan · WASHINGTON UNIVERSITY · 2024 · $561,330 — This application is to extend a MERIT award to study RNA synthesis in minus-strand RNA viruses. Nonsegmented negative-sense (NNS) RNA viruses include some of the most significant human pathogens that are an ongoing threat to US public health. For measles, mumps and rabies there are licensed vaccines…
Mehul Shamal Suthar · EMORY UNIVERSITY · 2024 · $752,750 — Humoral immunity is an essential component of the immune response to flavivirus infection. Primary infection generates a robust neutralizing antibody response that mediates viral control and protection. It is becoming increasingly apparent that secondary infection with a closely related flavivirus s…